Sabby Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Sabby Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-33	Closed	-$47K	–	132
2018 Q4	$47K	Buy	33 +6	+22%	+$245	0.01%	97
2018 Q3	$191K	Sell	27 -39	-59%	-$2.96K	0.02%	94
2018 Q2	$488K	Buy	66 +26	+65%	+$2.31K	0.08%	83
2018 Q1	$380K	Buy	40 +15	+60%	+$2.57K	0.05%	105
2017 Q4	$327K	Buy	+25	New	+$2.34K	0.03%	112
2017 Q3	–	Sell	-56	Closed	-$525K	–	214
2017 Q2	$525K	Buy	56 +10	+22%	+$1.15K	0.03%	136
2017 Q1	$661K	Buy	+46	New	+$6.58K	0.04%	160
2015 Q2	–	Sell	-19	Closed	-$993K	–	366
2015 Q1	$993K	Buy	+19	New	+$9.59K	0.04%	191
2014 Q4	–	Sell	-19	Closed	-$2.91K	–	283
2014 Q3	$2.91K	Buy	19 +1	+6%	+$1.45K	0.11%	83
2014 Q2	$2.48M	Buy	18 +3	+20%	+$3.48K	0.11%	91
2014 Q1	$2.08M	Buy	15 +8	+114%	+$9.3K	0.12%	104
2013 Q4	$672K	Buy	+7	New	+$7.24K	0.04%	140

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management's VIRX Position: Q1 2019 in Review

Sabby Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2019, closing a stake of 11,433 shares — an estimated $166K sold.

Sabby Management first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $1.09M in Q2 2018. 44 funds tracked by Wall St. Rank hold VIRX as of Q1 2019.

Sabby Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Sabby Management sold 11,433 Viracta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $166K.
Sabby Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
Sabby Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.09M in Q2 2018.
44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.